John Leonard
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medicine · New York, United States
Senior author of the landmark lenalidomide-rituximab trial in MCL. Senior Associate Dean for Innovation at Weill Cornell.
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.
Blood advances · Feb 24, 2026
Improvements in Outcomes in Older Patients With Mantle Cell Lymphoma Are Associated With Improvements Across Multiple Lines of Therapy.
Clinical lymphoma, myeloma & leukemia · Jun 1, 2025
Nodal T-Cell Lymphoma Transdifferentiated from Mantle Cell Lymphoma with Epstein-Barr Virus Infection.
Pathobiology : journal of immunopathology, molecular and cellular biology · Jan 1, 2025
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
Blood · Sep 5, 2024